CJ Bioscience, Inc. (KOSDAQ:311690)

South Korea flag South Korea · Delayed Price · Currency is KRW
8,030.00
-100.00 (-1.23%)
At close: Apr 28, 2026
-21.66%
Market Cap 104.92B
Revenue (ttm) 3.69B
Net Income (ttm) -24.00B
Shares Out 13.07M
EPS (ttm) -1,837.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 13,715
Average Volume 22,358
Open 8,130.00
Previous Close 8,130.00
Day's Range 7,900.00 - 8,130.00
52-Week Range 7,320.00 - 12,300.00
Beta 0.46
RSI 47.39
Earnings Date May 14, 2026

About CJ Bioscience

CJ Bioscience, Inc. provides microbiome solutions to address unmet medical needs in South Korea and internationally. The company’s platform is Ez-Mx, a bioinformatics-based platform for microbiome data analysis. Its product pipeline includes CJRB-101 that is phase I clinical trial for solid tumors; CJRB-201, CJRB-202, and CJRB-203 for inflammatory bowel diseases; CJRB-302 for Parkinson’s diseases; CJRB-401 and CJRB-402 for asthma. The company also provides next-generation sequencing analysis services; EzBioCloud, a database and bioinformatics a... [Read more]

Industry Computer Programming, Data Processing, And Other Computer Related Services
Founded 2009
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 311690
Full Company Profile

Financial Performance

In 2025, CJ Bioscience's revenue was 3.69 billion, an increase of 6.52% compared to the previous year's 3.47 billion. Losses were -24.00 billion, -26.90% less than in 2024.

Financial Statements

News

There is no news available yet.